Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinergic ligands.

Sonya L Palmer1, Ganesh A Thakur, Alexandros Makriyannis

  • 1Department of Pharmaceutical Sciences, University of Connecticut, 372 Fairdield Road, Storrs, CT 06269, USA.

Chemistry and Physics of Lipids
|December 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception.

Drug and alcohol dependence·2026
Same author

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same author

A critical role for α7 nicotinic acetylcholine receptor signaling in myeloid lineage cells in chronic neuropathic and inflammatory pain responses.

The journal of pain·2026
Same author

Microwave-accelerated conjugate addition of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators.

Journal of heterocyclic chemistry·2026
Same author

Library docking for Cannabinoid-2 Receptor ligands.

bioRxiv : the preprint server for biology·2026
Same author

Dopamine, γ-aminobutyric acid, and glutamate balance in the nucleus accumbens shell: Differential effects of cannabinoid 1 receptor agonists Δ<sup>9</sup>-Tetrahydrocannabinol, AM11101, and AM8936.

Neuropharmacology·2026

Advances in cannabinoid research reveal new therapeutic targets like the anandamide transporter. Inhibitors of this system show promise for treating pain and vascular disorders.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Biochemistry

Background:

  • The discovery of CB1 and CB2 receptors advanced understanding of the cannabinergic system.
  • Endogenous ligands like anandamide and 2-AG are key neuromodulators.
  • Metabolism involves FAAH and MAG lipase; a reuptake system for anandamide has been identified.

Purpose of the Study:

  • To review current cannabinergic ligands and probes.
  • To discuss their pharmacological and therapeutic potential.
  • To highlight therapeutic targets within the cannabinergic system.

Main Methods:

  • Characterization of anandamide reuptake system.
  • Development of selective transport inhibitors.
  • Synthesis of cannabimimetic ligands targeting cannabinoid proteins.

Related Experiment Videos

Main Results:

  • Anandamide transporter inhibitors show potential as analgesics and vasodilators.
  • Cannabinergic proteins (CB1, CB2, FAAH, anandamide transporter) are viable drug targets.
  • Designed ligands serve as molecular probes and pharmacological tools.

Conclusions:

  • Cannabinoid research has yielded significant therapeutic potential.
  • Targeting the endocannabinoid system offers avenues for treating diverse conditions.
  • Ligands and probes are crucial for understanding the endocannabinoid system's function.